DTx: value, impact, and expansion

In our second episode of Big Health Talks, we discuss how digital therapeutics transform patient care with a consultant pharmacist.

Welcome to the second segment of Big Health Talks, where we speak with clinical experts and benefits leaders about trends, challenges, and solutions in mental health care and the emerging field of digital therapeutics (DTx).

In this episode, Gabriela Perez, Chief Commercial Officer at Big Health, is joined by Cody Midlam, Director and Pharmacist Consultant at Willis Towers Watson. They discuss everything you need to know about DTx: the potential market, benefits, and predictions for the coming years.

How big is the potential market for DTx?

Where do you see DTx going in the next 2-3 years?

Who stands to benefit from the expansion of DTx, and how?

Watch and listen to the entire conversation between Gabriela and Cody below to learn more about the benefits of digital therapeutics.

Cody is a paid consultant for Big Health.
Sleepio and Daylight are available as an adjunct to usual medical care for insomnia disorder or generalized anxiety disorder, respectively, for adults ages 18 and older, without FDA review under their COVID-19 policy.

DOC-2919 Effective 06/2023

Digital Medicine

Mental Health

Mental Health Awareness

Copy Link

Subscribe to blog

Here’s our latest

5 trends that are reshaping the way employers approach benefits design

2024 marks the year of the employee benefits revolution, with more employers increasing their focus on driving innovation.

Blog /

min read

Sleep-deprived workforce? Boost productivity with better rest

Discover the high business costs of sleepless employees and get 5 key strategies for better sleep support.

Blog /

min read

Upgrade your EAP: Big Health's modern approach to employee well-being

End low EAP use with a reimagined employee experience from Big Health.

Blog /

min read

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. https://www.nice.org.uk/advice/mib129.5. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023